BETAMETHASONE VALERATE
Clinical safety rating: avoid
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
Betamethasone valerate is a corticosteroid that binds to the glucocorticoid receptor, leading to increased synthesis of lipocortin, which inhibits phospholipase A2 and reduces arachidonic acid release, thereby decreasing prostaglandin and leukotriene production. It also suppresses cytokine expression and inflammatory cell migration.
| Metabolism | Primarily hepatic via CYP3A4 and other microsomal enzymes; undergoes reduction, hydroxylation, and conjugation to inactive metabolites. |
| Excretion | Renal (primarily as metabolites, unchanged drug <5%). Biliary/fecal elimination accounts for a minor fraction. Essentially no significant renal excretion of active drug. |
| Half-life | Terminal elimination half-life is approximately 36–54 hours for the parent drug after topical application; systemic absorption is low. For oral or IV administration, the half-life is about 3–5 hours, but clinical effects persist longer due to receptor-mediated mechanisms. |
| Protein binding | Approximately 64% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd is about 0.6–1.2 L/kg, indicating distribution into total body water. Higher Vd suggests extensive tissue binding. |
| Bioavailability | Topical: systemic absorption is low (<1%–10% depending on skin condition and site; occlusive dressings increase absorption). Oral: approximately 70–100% absorbed. Intramuscular: essentially complete. Avoid IV formulation; betamethasone sodium phosphate or acetate used parenterally. |
| Onset of Action | Topical: improvement noted within 12–24 hours; maximum effect after several days. Intralesional: onset within a few hours to days. Oral/IV: rapid onset within hours for systemic effects. |
| Duration of Action | Topical: duration of action 12–24 hours after single application; repeated daily use for sustained effect. Intralesional: effects may last weeks. Systemic: duration of adrenal suppression may persist for days after cessation. |
| Molecular Weight | 476.58 |
Apply a thin film to affected area twice daily. Maximum 15 g/day for 2 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Apply a thin film to affected area once to twice daily for no more than 2 weeks. Use the lowest potency preparation and smallest amount possible. Avoid use in diaper area or under occlusion. |
| Geriatric use | Use with caution due to thinner skin and increased risk of systemic absorption. Apply sparingly for shortest duration necessary. |
| 1st trimester | Topical corticosteroids, including betamethasone valerate, should be used during the first trimester only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown teratogenicity with high doses, but human data are limited. Avoid prolonged use or application to large areas. |
| 2nd trimester | Use with caution; similar considerations as in the first trimester. Prolonged or high-dose use may increase risk of fetal growth restriction. Use the lowest effective dose for the shortest duration possible. |
| 3rd trimester | Use with caution; risk of fetal growth restriction with prolonged or high-dose use. Near term, use may be associated with neonatal adrenal suppression. Avoid application to large areas or occlusive dressings. |
Clinical note
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
| FDA category | Positive |
| Placental transfer |
■ FDA Black Box Warning
No FDA boxed warning exists for betamethasone valerate.
| Common Effects | Hyperglycemia |
| Serious Effects |
Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, vaccinia, varicella)Hypersensitivity to betamethasone valerate or any component of the formulationRosaceaPerioral dermatitis
| Precautions | Systemic absorption may cause reversible HPA axis suppression, especially with prolonged use on large areas or under occlusion, Local adverse reactions include atrophy, striae, telangiectasias, and secondary infection, Use in children may lead to growth retardation and Cushing's syndrome, Avoid use on face, groin, or axillae unless directed, Discontinue if irritation or allergic dermatitis occurs |
| Food/Dietary | No known food interactions. Avoid excessive intake of foods that may cause histamine release if treating allergic dermatitis (e.g., aged cheese, fermented foods) as a precaution. |
Loading safety data…
| Corticosteroids including betamethasone cross the placenta. The degree of transfer is dependent on the formulation and route; topical application results in minimal systemic absorption (approximately 1-2% in healthy skin, higher in damaged skin), thus placental transfer is expected to be low with cautious use. |
| Breastfeeding | Betamethasone valerate is excreted into breast milk in small amounts after topical application, but systemic absorption is low. However, if applied to large areas or under occlusion, systemic levels may increase. Use the lowest effective dose on the smallest area for the shortest duration. Avoid application to the breast or nipple area to prevent infant ingestion. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Corticosteroids are associated with a small increased risk of orofacial clefts (odds ratio ~1.3–1.5). Second and third trimesters: Prolonged maternal use may increase risk of fetal adrenal suppression, intrauterine growth restriction (IUGR), and premature rupture of membranes due to anti-anabolic effects. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (especially in diabetic patients), and signs of infection. In late pregnancy, assess fetal growth via ultrasound if prolonged therapy. In neonates exposed in utero, monitor for signs of adrenal insufficiency (e.g., hypoglycemia, lethargy) and infection. |
| Fertility Effects | No direct evidence of fertility impairment in humans at therapeutic doses. In animal studies, high-dose corticosteroids may disrupt estrous cycles and implantation. Clinical significance is minimal with topical use due to low systemic absorption. |
| Clinical Pearls | Betamethasone valerate is a potent topical corticosteroid (class III/IV). Apply sparingly to affected areas only; avoid use on face, groin, or axillae due to increased risk of skin atrophy. Limit continuous use to 2 weeks; taper or discontinue gradually to avoid rebound. Systemic absorption possible with extensive application or occlusive dressings, especially in children. Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use. |
| Patient Advice | Apply a thin layer to affected skin only; do not cover with bandages unless directed by your doctor. · Wash hands after application unless treating hands. · Avoid contact with eyes, mouth, and open wounds. · Do not use for more than 2 weeks continuously without consulting your provider. · Report any signs of skin thinning, infection, or unusual bruising. · Do not use on children without medical advice. · Use only as prescribed; overuse can lead to serious side effects. |